London, May 4, 2026, 15:03 BST
Halma plc heads into a shortened London trading week with its shares close to a one-year high, after the stock rose 2.72% on Friday to close at £45.27 while the FTSE 100 slipped 0.14%. The latest close left the UK safety, environmental and healthcare technology group 1.15% below its 52-week high of £45.80.
That matters now because London trading is shut on Monday for the Early May Bank Holiday, leaving Friday’s close as the market’s last price before investors turn harder toward Halma’s June 11 full-year results. The London Stock Exchange calendar lists May 4 as a non-trading day.
The company has already set a high bar. In its March trading update, Halma said it expected mid-teens organic constant- currency revenue growth, meaning growth that strips out foreign exchange moves and the first-year effect of acquisitions and disposals, and an adjusted EBIT margin of about 22%. Adjusted EBIT is operating profit before interest, tax and certain acquisition-related and other items.
The latest portfolio move came from the other side of the ledger. Cardioline said on April 30 it acquired Cardios, a São Paulo-based maker of Holter monitors and ambulatory blood-pressure monitoring products, from Halma. Holter monitors are wearable devices used to track heart rhythm over a longer period than a standard clinic test. Terms were not disclosed. Cardioline CEO Luis Meireles said the deal opened a “new geographic hub,” while Cardios CEO Erica Chriguer said the combination would add Cardioline’s stress-test and electrocardiography products to Cardios’s portfolio. Cardioline
Halma has also been buying. On April 13, it said it acquired Surgistar, a California-based maker of ophthalmic surgical instruments, as a bolt-on for MicroSurgical Technology, its healthcare-sector business. Chief Executive Marc Ronchetti called cataract and ophthalmic surgery “long term growth markets” and said Surgistar would add products used in routine cataract surgery. Halma
The group’s broader deal pace has picked up. Halma said in March it had completed five acquisitions in the financial year to date, three since Sept. 30, with a record £451 million invested on a maximum total consideration basis. It also said order intake remained ahead of both revenue in the year to date and the comparable period last year.
The rally was stronger than the latest move in some UK specialist engineering names. Trading Economics data showed IMI down 2.01% and Renishaw up 0.46% on May 1, compared with Halma’s 2.72% gain. They are not direct peers, but they sit in the same broad UK industrial technology field that investors often use as a valuation check.
There is a catch. The share price has moved ahead of the average analyst target shown by Investing.com, which put the 12-month consensus target at 4,032.6 pence, implying about 10.9% downside from the latest listed price. The same data showed 8 buy ratings, 8 holds and 2 sells, a split that suggests support for the business but less agreement on the price.
Currency is another drag to watch. Halma said sterling’s strength against the U.S. dollar and euro was expected to cut reported 2026 revenue by about £63 million and profit by about £14 million versus 2025. That is not an operating failure, but it can still blunt the headline numbers.
Halma’s structure gives investors a wide mix to judge. Reuters describes the company as operating across Safety, Environmental & Analysis and Healthcare, with products ranging from fire safety and worker safety technology to water analysis, optoelectronic applications and healthcare devices. That breadth is part of the appeal; it also means June’s results will need to show that growth is not resting on one hot pocket of demand.
